Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
VAMAS1
MCID: VTL004
MIFTS: 64

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 (VAMAS1)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases, Smell/Taste diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 58 30 13 6 39 41 74
Vitiligo 58 39 12 77 54 26 38 56 6 44 45 15 17 74
Vamas1 58 76
Slev1 58 76
Vtlg 58 26
Systemic Lupus Erythematosus, Vitiligo-Related; Slev1 58
Vitiligo-Associated Multiple Autoimmune Disease 1 76
Systemic Lupus Erythematosus, Vitiligo-Related 58
Systemic Lupus Erythematosus Vitiligo-Related 76
Vitiligo; Vtlg 58

Characteristics:

HPO:

33
vitiligo-associated multiple autoimmune disease susceptibility 1:
Inheritance polygenic inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases Smell/Taste diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:12306
OMIM 58 606579
KEGG 38 H01372
ICD9CM 36 709.01
NCIt 51 C26915
SNOMED-CT 69 56727007
ICD10 34 L80
MedGen 43 C1847835
Sources

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section
NIH Rare Diseases : 54 Vitiligo is a relatively common pigmentation disorder in which the skin's pigment-making cells (melanocytes) are lost or destroyed. As a result, well-defined white patches appear on the skin. Patches may occur on one section or all over the body and may join together (coalesce). Some people also have loss of pigment in patches of hair on the head or body. Vitiligo tends to continue over time, causing larger areas of skin to lose pigment. It may begin at any age but the average age of onset is in the mid-twenties. Vitiligo does not affect physical health, but concerns about appearance and ethnic identity can lead to serious psychological, social, and emotional difficulties, significantly impacting quality of life. The specific cause of vitiligo is not known. Many people with vitiligo also have a personal or family history of autoimmune disease, suggesting that vitiligo has an autoimmune cause. It sometimes "runs in families,"  suggesting that genetics may play a role. People with vitiligo often report that its onset was related to a specific triggering event, such as injury, illness, sunburn, emotional stress, or pregnancy. However, there are currently no data supporting that these factors cause vitiligo. There is no cure for vitiligo, but available treatments may stop its progression and induce varying degrees of re-pigmentation. Treatment options vary depending on severity and preference and may include topical, systemic, and/or light-based therapies. A combination of therapies is usually more effective than a single therapy. Despite the availability of treatment, the course of the condition and response to treatment are unpredictable.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1, also known as vitiligo, is related to alopecia areata and halo nevi, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 is NLRP1 (NLR Family Pyrin Domain Containing 1), and among its related pathways/superpathways are NOD-like receptor signaling pathway and NF-kappaB Signaling. The drugs Tacrolimus and mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and t cells, and related phenotypes are vitiligo and homeostasis/metabolism

Disease Ontology : 12 An autoimmune hypersensitivity disease that causes depigmentation of patches of skin resulting from loss of function or death of melanoctyes.

Genetics Home Reference : 26 Vitiligo is a condition that causes patchy loss of skin coloring (pigmentation). The average age of onset of vitiligo is in the mid-twenties, but it can appear at any age. It tends to progress over time, with larger areas of the skin losing pigment. Some people with vitiligo also have patches of pigment loss affecting the hair on their scalp or body.

OMIM : 58 Generalized vitiligo is an autoimmune disease characterized by melanocyte loss, which results in patchy depigmentation of skin and hair, and is associated with an elevated risk of other autoimmune diseases. It is a genetically complex disorder involving multiple susceptibility genes and unknown environmental triggers. Patients with generalized vitiligo have elevated frequencies of other autoimmune diseases, suggesting that these diseases involve shared genetic components (summary by Jin et al., 2010). (606579)

MedlinePlus : 44 Vitiligo causes white patches on your skin. It can also affect your eyes, mouth, and nose. It occurs when the cells that give your skin its color are destroyed. No one knows what destroys them. It is more common in people with autoimmune diseases, and it might run in families. It usually starts before age 40. The white patches are more common where your skin is exposed to the sun. In some cases, the patches spread. Vitiligo can cause your hair to gray early. If you have dark skin, you may lose color inside your mouth. Using sunscreen will help protect your skin, and cosmetics can cover up the patches. Treatments for vitiligo include medicines, light therapy, and surgery. Not every treatment is right for everyone. Many have side effects. Some take a long time. Some do not always work. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

UniProtKB/Swiss-Prot : 76 Vitiligo-associated multiple autoimmune disease 1: A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.

Wikipedia : 77 Vitiligo is a long-term skin condition characterized by patches of the skin losing their pigment. The... more...

Sources

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)
# Related Disease Score Top Affiliating Genes
1 alopecia areata 32.8 AIRE CTLA4 PTPN22
2 halo nevi 32.6 PMEL TYR
3 piebald trait 32.3 KITLG MITF TYR
4 vogt-koyanagi-harada disease 32.1 NLRP1 PMEL PTPN22 TYR TYRP1
5 vitiligo-associated multiple autoimmune disease susceptibility 6 31.7 AIRE CAT MITF PCBD1 PMEL PTPN22
6 thyroiditis 30.7 CTLA4 PTPN22 TPO
7 hypoadrenocorticism, familial 30.6 AIRE CTLA4 DDC POMC PTPN22 TPO
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 AIRE CTLA4 PTPN22 TPO
9 autoimmune disease 30.4 AIRE CTLA4 NLRP1 PTPN22 TPO
10 pernicious anemia 30.3 AIRE TPO
11 albinism 30.3 MITF TYR TYRP1
12 lupus erythematosus 30.2 C4B CTLA4 NLRP1 PTPN22
13 amelanotic melanoma 30.2 CAT TYR TYRP1
14 hashimoto thyroiditis 30.2 AIRE CTLA4 PTPN22 TPO
15 microphthalmia 30.1 MITF PMEL TYR TYRP1
16 graves' disease 30.0 CTLA4 PTPN22 TPO
17 hypomelanosis of ito 29.9 MITF TYR
18 hypothyroidism 29.9 AIRE CTLA4 POMC TPO
19 celiac disease 1 29.9 CTLA4 PTPN22 TPO
20 melanoma, uveal 29.8 MITF PMEL TYR
21 autoimmune hepatitis 29.7 AIRE CTLA4 DDC
22 skin melanoma 29.7 FGF2 MITF PMEL TYR
23 waardenburg's syndrome 29.5 KITLG MITF TYR TYRP1
24 deafness, congenital, with vitiligo and achalasia 12.4
25 alopecia universalis onychodystrophy vitiligo 12.3
26 vitiligo, progressive, with mental retardation and urethral duplication 12.1
27 autoimmune disease 1 12.0
28 spastic paraplegia 23, autosomal recessive 11.9
29 schrander-stumpel theunissen hulsmans syndrome 11.5
30 autoimmune polyglandular syndrome type 3 11.5
31 hemifacial atrophy, progressive 11.3
32 autoimmune atrophic gastritis 11.3
33 alezzandrini syndrome 11.2
34 autoimmune disease 2 11.2
35 autoimmune disease 3 11.2
36 autoimmune disease 4 11.2
37 stiff-person syndrome 11.1
38 hereditary spastic paraplegia 23 11.0
39 ermine phenotype 11.0
40 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.0
41 nijmegen breakage syndrome 11.0
42 lelis syndrome 11.0
43 t-cell receptor-alpha/beta deficiency 11.0
44 hypopigmentation of eyelid 11.0
45 combined immunodeficiency with skin granulomas 11.0
46 gemignani syndrome 11.0
47 melanoma 10.6
48 alopecia 10.5
49 psoriasis 10.5
50 gallbladder melanoma 10.4 MITF PMEL

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1
Sources

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

33
# Description HPO Frequency HPO Source Accession
1 vitiligo 33 HP:0001045

Clinical features from OMIM:

606579

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:


pruritus, exanthema

MGI Mouse Phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 AIRE C4B CAT CTLA4 DDC FGF2
2 hematopoietic system MP:0005397 10.26 AIRE C4B CTLA4 FGF2 KITLG MITF
3 cardiovascular system MP:0005385 10.24 C4B CTLA4 DDC FGF2 GCH1 KITLG
4 growth/size/body region MP:0005378 10.21 AIRE DDC KITLG MCHR1 MITF POMC
5 mortality/aging MP:0010768 10.21 AIRE C4B CAT CTLA4 DDC FGF2
6 immune system MP:0005387 10.17 AIRE C4B CTLA4 DDC KITLG MITF
7 endocrine/exocrine gland MP:0005379 10.13 AIRE CTLA4 KITLG MITF POMC PTPN22
8 integument MP:0010771 10.01 CTLA4 KITLG MITF PCBD1 PMEL POMC
9 hearing/vestibular/ear MP:0005377 9.97 FGF2 KITLG MITF TPO TYR TYRP1
10 nervous system MP:0003631 9.96 AIRE DDC FGF2 GCH1 KITLG MCHR1
11 neoplasm MP:0002006 9.87 AIRE CAT FGF2 KITLG POMC TYR
12 pigmentation MP:0001186 9.76 CTLA4 KITLG MITF PCBD1 PMEL POMC
13 skeleton MP:0005390 9.56 CTLA4 FGF2 KITLG MCHR1 MITF TPO
14 vision/eye MP:0005391 9.32 AIRE DDC FGF2 KITLG MITF PCBD1
Sources

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
2
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
3
Pimecrolimus Approved, Investigational Phase 4,Phase 2 137071-32-0 17753757 6447131
4
Fluticasone Approved, Experimental Phase 4,Not Applicable,Early Phase 1 90566-53-3 62924
5
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
6
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
7
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
8
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
9
Insulin glulisine Approved Phase 4 207748-29-6
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Not Applicable 302-79-4 444795 5538
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Dermatologic Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Analgesics Phase 4,Phase 2,Not Applicable
15 Analgesics, Non-Narcotic Phase 4,Phase 2
16 Anti-Allergic Agents Phase 4,Not Applicable,Early Phase 1
17 Antirheumatic Agents Phase 4,Phase 2,Phase 1
18 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
19 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
23 Autonomic Agents Phase 4,Not Applicable,Early Phase 1
24 Bronchodilator Agents Phase 4,Not Applicable,Early Phase 1
25 Respiratory System Agents Phase 4,Not Applicable,Early Phase 1
26 Anti-Asthmatic Agents Phase 4,Not Applicable,Early Phase 1
27 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Not Applicable
28 Amotosalen Phase 4,Phase 2
29 Ficusin Phase 4,Phase 2
30 Furocoumarins Phase 4,Phase 2
31 Protective Agents Phase 4,Phase 3,Not Applicable
32 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Ophthalmic Solutions Phase 4,Phase 2,Phase 3
37 Antihypertensive Agents Phase 4,Phase 2,Phase 3
38 Botulinum Toxins Phase 4
39 Neurotransmitter Agents Phase 4
40 Botulinum Toxins, Type A Phase 4
41 Acetylcholine Release Inhibitors Phase 4
42 Neuromuscular Agents Phase 4
43 abobotulinumtoxinA Phase 4
44 Cholinergic Agents Phase 4
45 Radiation-Protective Agents Phase 4,Not Applicable
46 Antioxidants Phase 4,Not Applicable
47 Keratolytic Agents Phase 4,Not Applicable
48 Hylan Phase 4
49 insulin Phase 4,Not Applicable
50 Hypoglycemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
2 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
3 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
4 Punchgrafting Techniques for Vitiligo Unknown status NCT01377077 Phase 4
5 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Unknown status NCT01640678 Phase 4
6 Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Not yet recruiting NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
7 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Recruiting NCT03199664 Phase 4
8 NB-UVB and PUVA Vitiligo Study Completed NCT01732965 Phase 4
9 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
10 Topical Bimatoprost Solution 0.03%in Stable Vitiligo Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
11 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Completed NCT02458417 Phase 4
12 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4 Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
13 A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. Completed NCT00293163 Phase 4
14 Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Enrolling by invitation NCT02914886 Phase 4 Apidra;current insulin
15 Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
16 Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol Unknown status NCT00525395 Phase 3
17 A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Unknown status NCT02156427 Phase 3
18 Microneedling and Latanoprost in Acrofacial Vitiligo Not yet recruiting NCT03611348 Phase 2, Phase 3 Latanoprost
19 Vitiligo Skin Transplantation Completed NCT00830713 Phase 3
20 Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
21 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
22 Epidermal Cell Transplantation in Vitiligo Skin Completed NCT01629979 Phase 2, Phase 3
23 Excimer Lamp Versus Excimer Laser in Vitiligo Treatment Completed NCT00696358 Phase 3
24 Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
25 Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo Completed NCT00807690 Phase 3 Tacrolimus ointment
26 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
27 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
28 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
29 Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds Completed NCT01205061 Phase 3
30 Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) Completed NCT01345240 Phase 3
31 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
32 Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects Recruiting NCT03627767 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Placebo
33 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Recruiting NCT03422822 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Placebo;PF-04965842 100 mg
34 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) Completed NCT02608450 Phase 3 CB-03-01 cream, 1%;Vehicle cream
35 Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
36 Efficacy of Red Light in Vitiligo Unknown status NCT01787708 Phase 2
37 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
38 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
39 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand Unknown status NCT01792245 Phase 2
40 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO Active, not recruiting NCT03036995 Phase 2 Apremilast
41 A Study of Ruxolitinib Phosphate Cream in Subjects With Vitiligo Active, not recruiting NCT03099304 Phase 2 Ruxolitinib cream;Vehicle cream
42 Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo Recruiting NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
43 Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Active, not recruiting NCT03123016 Phase 2 Apremilast
44 Clinical Trial of Simvastatin to Treat Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
45 Atorvastatin in Active Vitiligo Completed NCT02432534 Phase 2 Atorvastatin
46 Topical Ruxolitinib for the Treatment of Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
47 Melanocyte Transplantation for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
48 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
49 Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo Terminated NCT01923142 Phase 2
50 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
JACE, cultured epidermis for skin replacement
Embryonic/Adult Cultured Cells Related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
Cultured epidermis (JACE�) PMIDs: 23265935 17465819 11987545

Cochrane evidence based reviews: vitiligo

Sources

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Genetic tests related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

# Genetic test Affiliating Genes
1 Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 30 NLRP1
Sources

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

42
Skin, Thyroid, T Cells, Eye, Testes, Neutrophil, Myeloid
Sources

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

(show top 50) (show all 2996)
# Title Authors Year
1
Dermatitis herpetiformis arising within vitiligo in a patient with autoimmune polyendocrine syndrome type 3. ( 30924131 )
2019
2
Coexistence of segmental vitiligo, scleroderma en coup de sabre and cleft lip on the same hemiface: association with mosaicism? ( 31090840 )
2019
3
Contact Dermatitis Due to Black Pepper Extract Used to Treat Vitiligo. ( 29937061 )
2019
4
Gender Differences in Depression, Coping, Stigma, and Quality of Life in Patients of Vitiligo. ( 31065260 )
2019
5
Study on Assessment of Quality of Life and Depression in Patients of Vitiligo. ( 30984590 )
2019
6
The impact of therapeutic modalities on patients with atopic dermatitis, psoriasis and vitiligo treated with phototherapy in the Jagiellonian University Outpatient Clinic. ( 30912521 )
2019
7
Vitiligo and major depressive disorder: A bidirectional population-based cohort study. ( 30528503 )
2019
8
Regional vitiligo induced by imiquimod treatment for in-transit melanoma metastases. ( 31065581 )
2019
9
Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment. ( 31017249 )
2019
10
Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma. ( 30985014 )
2019
11
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy. ( 30939167 )
2019
12
Genetic and environmental risk factors for vitiligo and melanoma in Pura Raza Español horses. ( 30624804 )
2019
13
Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response. ( 30281140 )
2019
14
A Nationwide, Population-based Cohort Study on Potential Autoimmune Association of Ménière Disease to Atopy and Vitiligo. ( 30867466 )
2019
15
Valcyclovir as a potential therapy for Mycosis Fungoides and Vitiligo in a Zosteriform pattern. ( 30838701 )
2019
16
Onychomatricoma in a Patient with Extensive Vitiligo: Answer. ( 30688728 )
2019
17
Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis. ( 30773437 )
2019
18
Vitiligo in a patient receiving infliximab for chronic plaque psoriasis. ( 30994249 )
2019
19
Association Between Psoriasis and Vitiligo: A Systematic Review and Meta-Analysis. ( 30317450 )
2019
20
Trichomegaly induced by topical tacrolimus for the treatment of periorbital vitiligo: A brief report of a new adverse effect. ( 31070265 )
2019
21
Vitiligo and melanocytic nevi: New findings in Coffin-Siris syndrome associated with ARID1 germline mutation. ( 30581937 )
2019
22
The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study. ( 30849210 )
2019
23
The effectiveness of topical therapy combined with 308-nm excimer laser on vitiligo compared to excimer laser monotherapy in pediatric patients. ( 30520111 )
2019
24
A multi-center, randomized, split face and/or neckcomparisonof 308-nm excimer laser and0·1%tacrolimus ointmentfor stable vitiligo, plus intramuscular slow releasing betamethasone for active vitiligo. ( 30644997 )
2019
25
Comparison of 311-nm Titanium:Sapphire laser and 308-nm excimer laser treatment for vitiligo: A randomized controlled non-inferiority trial. ( 30681166 )
2019
26
A preliminary study of fractional CO2 laser added to topical tacrolimus combined with 308 nm excimer lamp for refractory vitiligo. ( 30238584 )
2019
27
The effectiveness of combination therapy with 308-nm excimer laser in vitiligo in Han Chinese People. ( 29974452 )
2019
28
The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios. ( 30280485 )
2019
29
The role of IFIH1 gene rs1990760 and rs2111485 single-nucleotide polymorphisms in generalized vitiligo predisposition ( 30761886 )
2019
30
Use of platelet-rich plasma to suspend noncultured epidermal cell suspension improves repigmentation after autologous transplantation in stable vitiligo: a double-blind randomized controlled trial. ( 30506679 )
2019
31
5-Fluorouracil as an adjuvant therapy along with microneedling in vitiligo. ( 30529709 )
2019
32
Baicalin and berberine ultradeformable vesicles as potential adjuvant in vitiligo therapy. ( 30590326 )
2019
33
Efficacy of Transplantation of Combination of Noncultured Dermal and Epidermal Cell Suspension vs Epidermal Cell Suspension Alone in Vitiligo: A Randomized Clinical Trial. ( 30601885 )
2019
34
Coexisting cutaneous disorders in vitiligo: a retrospective analysis. ( 30604508 )
2019
35
Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. ( 30618056 )
2019
36
Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. ( 30636075 )
2019
37
Comparison of prognosis in centrofacial, panfacial and hairline vitiligo: a prospective cohort study. ( 30640572 )
2019
38
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies. ( 30650959 )
2019
39
Changes in sICAM-1 and GM-CSF levels in skin tissue fluid and expression of IL-6, IL-17 and TNF-α in blood of patients with vitiligo. ( 30651813 )
2019
40
Risk of neurodegenerative disorders in Korean patients with vitiligo: A nationwide retrospective cohort study. ( 30654072 )
2019
41
Microneedling with dermaroller 192 needles along with 5-fluorouracil solution in the treatment of stable vitiligo. ( 30654074 )
2019
42
Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells. ( 30655106 )
2019
43
Association of glucose 6-phosphate dehydrogenase (G6PD) 3'UTR polymorphism with vitiligo and in vitro studies on G6PD inhibition in melanocytes. ( 30658872 )
2019
44
Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. ( 30674883 )
2019
45
Quality of life of adult vitiligo patients using camouflage: A survey in a Chinese vitiligo community. ( 30677057 )
2019
46
New insights in vitiligo treatments using bioactive compounds from Piper nigrum. ( 30679971 )
2019
47
The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. ( 30683146 )
2019
48
Mechanisms of repigmentation induced by photobiomodulation therapy in vitiligo. ( 30698884 )
2019
49
Assessment of telomerase activity in nonsegmental vitiligo tissue: a pilot study. ( 30706515 )
2019
50
T-cell responses against 4-tertiarybutylphenol-exposed pigmented cells in a patient with occupational vitiligo. ( 30719700 )
2019
Sources

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

76
# Symbol AA change Variation ID SNP ID
1 NLRP1 p.Leu155His VAR_033239 rs12150220

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NLRP1 NM_001033053.2(NLRP1): c.464T> A (p.Leu155His) single nucleotide variant risk factor rs12150220 GRCh37 Chromosome 17, 5485367: 5485367
2 NLRP1 NM_001033053.2(NLRP1): c.464T> A (p.Leu155His) single nucleotide variant risk factor rs12150220 GRCh38 Chromosome 17, 5582047: 5582047
3 KIF1B NM_015074.3(KIF1B): c.4387C> T (p.Arg1463Cys) single nucleotide variant Uncertain significance rs757850683 GRCh37 Chromosome 1, 10425479: 10425479
4 KIF1B NM_015074.3(KIF1B): c.4387C> T (p.Arg1463Cys) single nucleotide variant Uncertain significance rs757850683 GRCh38 Chromosome 1, 10365421: 10365421
Sources

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section
Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1.
Sources

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Pathways related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to KEGG:

38
# Name Kegg Source Accession
1 NOD-like receptor signaling pathway hsa04621

Pathways related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
12.14 CTLA4 KITLG NLRP1 PTPN22
2
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.67 FGF2 KITLG MITF
3
Differentiation Pathway 1
10.81 FGF2 KITLG TPO
4
Melanocyte Development and Pigmentation 65
10.41 KITLG MITF POMC
5
Dopamine metabolism 1
10.4 DDC TYR
6
Melanin biosynthesis 67
9.85 TYR TYRP1
Sources

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section

Cellular components related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome GO:0042470 9.13 PMEL TYR TYRP1
2 melanosome membrane GO:0033162 8.62 TYR TYRP1

Biological processes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.83 CAT PCBD1 TPO TYR TYRP1
2 melanocyte differentiation GO:0030318 9.4 MITF TYRP1
3 melanosome organization GO:0032438 9.37 PMEL TYRP1
4 embryonic hemopoiesis GO:0035162 9.32 KITLG TPO
5 dopamine biosynthetic process GO:0042416 9.26 DDC GCH1
6 tetrahydrobiopterin biosynthetic process GO:0006729 9.16 GCH1 PCBD1
7 pigmentation GO:0043473 9.13 MITF TYR TYRP1
8 melanin biosynthetic process GO:0042438 8.8 PMEL TYR TYRP1
Sources

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....